Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients

Schizophrenia Research

Volumn 147, Issue 2-3, 2013, Pages 236-240

  Hui, Li ^a   Zhang, Xuan ^a   Yu, Ya Qin ^a   Han, Mei ^b,c   Huang, Xu Feng ^b,c   Chen, Da Chun ^d   Wang, Zhi Ren ^d   Du, Wei Li ^a   Kou, Chang Gui ^a   Yu, Qiong ^a   Kosten, Thomas R ^d,e   Zhang, Xiang Yang ^d,e  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d PEKING UNIVERSITY   (China)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Association; Cognitive function; Dopamine beta hydroxylase; First episode schizophrenic patients; Genotype

Indexed keywords

DOPAMINE BETA MONOOXYGENASE;

ADULT; ALLELE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DBH GENE; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SCORING SYSTEM; VISUOSPATIAL CONSTRUCTIONAL INDEX; ADOLESCENT; COGNITION DISORDERS; COMPLICATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NONPARAMETRIC TEST; NUCLEOTIDE SEQUENCE; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADOLESCENT; ADULT; BASE SEQUENCE; COGNITION DISORDERS; DOPAMINE BETA-HYDROXYLASE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEQUENCE DELETION; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84878975796     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.04.035     Document Type: Article

References (58)

1. Addington J., Brooks B.L., Addington D. Cognitive functioning in first episode psychosis: initial presentation. Schizophr. Res. 2003, 62:59-64.
2. Arnsten A.F. Stress impairs prefrontal cortical function in rats and monkeys: role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms. Prog. Brain Res. 2000, 126:183-192.
3. Bozikas V.P., Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust. N. Z. J. Psychiatry 2011, 45(2):93-108.
4. Braver T.S., Barch D.M., Cohen J.D. Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. Biol. Psychiatry 1999, 46(3):312-328.
5. Bridge T.P., Phelps B.H., Cutler N.R., Jeste D.V., Wyatt R.J. Peripheral catecholamine enzyme function and cognitive impairment of elderly schizophrenics and controls. J. Am. Geriatr. Soc. 1984, 32(4):259-264.
6. Christopher M.W., James M.G., John J.B., Faith D., Wayne S.F., Michael K., Christopher R., Robert W. Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am. J. Psychiatry 2002, 159:838-844.
7. Cubells J.F., Zabetian C.P. Human genetics of plasma dopamine betahydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl) 2004, 174:463-476.
8. Cubells J.F., Kobayashi K., Nagatsu T., Kidd K.K., Kidd J.R., Calafell F., Kranzler H.R., Ichinose H., Gelernter J. Population genetics of a functional variant of the dopamine beta-hydroxylase gene (DBH). Am. J. Med. Genet. 1997, 74(4):374-379.
9. Cubells J.F., van Kammen D.P., Kelley M.E., Anderson G.M., O' Connor D.T., Price L.H., Malison R., Rao P.A., Kobayshi K., Nagatsu T., Gelernter J. Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum. Genet. 1998, 102(5):533-540.
10. Cubells J.F., Kranzler H.R., McCance-Katz E., Anderson G.M., Malison R.T., Price L.H., Gelemter J. A haplotype at the DBH locus, associated with low plasma dopamine betahydroxylase activity, also associates with cocaine-induced paranoia. Mol. Psychiatry 2000, 5:56-63.
11. Daban C., Amado I., Bourdel M.C., Loo H., Olie J.P., Poirier M.F., Krebs M.O. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. Psychiatr. Res. 2005, 39:391-398.
12. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148:1474-1486.
13. Dickerson F., Boronow J.J., Stallings C., Origoni A.E., Cole S.K., Yolken R.H. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Res. 2004, 129(1):45-53.
14. Frank M.J., Santamaria A., O'Reilly R.C., Willcutt E. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2007, 32:1583-1599.
15. Friedman J.L., Adler D.N., Davis K.L. The Role of Norepinephrine in the Pathophysiology of Cognitive Disorders: Potential Applications to the Treatment of Cognitive Dysfunction in Schizophrenia and Alzheimer's Disease. Biol. Psychiatry 1999, 46:1243-1252.
16. Gauderman W.J. Sample size requirements for matched case-control studies of gene environment interaction. Stat. Med. 2002, 21:35-50.
17. Gogos A., Joshua N., Rossell S.L. Use of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to investigate group and gender differences in schizophrenia and bipolar disorder. Aust. N. Z. J. Psychiatry 2010, 44(3):220-229.
18. Gong P.Y., Li J., Chi W.Y., Wang J., Yao T.B., Zhang K.J., Gao X.C., Zhang F.C. Variants in COMT and DBH influence on response inhibition ability in Chinese Han females. Cell. Mol. Neurobiol. 2011, 31(8):1163-1169.
19. Gong P.Y., Xi S.M., Shen G.M., Li S., Zhang P.Z., Cao G.C., Zhang F.C., Shen Y., Feng T.T., Ma H. The effects of DBH, MAOA, and MAOB on attentional biases for facial expressions. J. Mol. Neurosci. 2013, 49:606-613.
20. Granholm E., McQuaid J.R., Link P.C., Fish S., Patterson T., Jeste D.V. Neuropsychological predictors of functional outcome in cognitive behavioral social skills training for older people with schizophrenia. Schizophr. Res. 2008, 100(1-3):133-143.
21. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72:41-51.
22. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S., Kern R.S., Kraemer H., Stover E., Weinberger D.R., Zalcman S., Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 2004, 56(5):301-307.
23. Han M., Huang X.F., Chen D.C., Xiu M.H., Hui L., Liu H., Kosten T.R., Zhang X.Y. Gender differences in cognitive function of patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39(2):358-363.
24. Harvey P.D. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol. Rev. 2009, 19:324-335.
25. Harvey P.D., Geyer M.A., Robbins T.W., Krystal J.H. Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology 2003, 169:213-214.
26. Heaton R., Paulsen J.S., Mcadams L.A., Zisook S., Braff D., Harris J., Jeste D.V. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch. Gen. Psychiatry 1994, 51:469-476.
27. Histoshi S., Robert R.S., Scott T.S., Richard S.E.K., Tarek R., Takefumi S., David C.M., Bruce G.P., Koichiro W., Masaru M., Hiroyuki U. Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. Schizophr. Bull. 2013, 39(3):564-574.
28. Hoff A.L., Sakuma M., Wieneke M., Horon R., Kushner M., Delisi L.E. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am. J. Psychiatry 1999, 56:1336-1341.
29. Hughes C., Kumari V., Soni W., Das M., Binneman B., Drozd S., O'Neil S., Mathew V., Sharma T. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr. Res. 2003, 59(2-3):137-146.
30. Hui L., Zhang X., Huang X.F., Han M., Fernandez F., Yu Y., Sun S., Li W., Chen D.C., Xiu M.H., Kosten T.R., Zhang X.Y. The dopamine b-hydroxylase 19bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia. J. Psychiatr. Res. 2012, 46(6):733-737.
31. Jonsson E.G., Abou J.R., Schumacher J., Flyckt L., Edman G., Forslund K., Mattila-Evenden M., Rylander G., Asberg M., Bjerkenstedt L., Wiesel F.A., Propping P., Cichon S., Nothen M.M., Sedvall G.C. No association between a putative functional promoter variant in the dopamine beta-hydroxylase gene and schizophrenia. Psychiatr. Genet. 2003, 13(3):175-178.
32. Kaneda Y., Jayathilak K., Meltzer H.Y. Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function. Psychiatry Res. 2009, 169(2):178-179.
33. Kieling C., Genro J.P., Hutz M.H., Rohde L.A. The -1021 C/T DBH polymorphism is associated with neuropsychological performance among children and adolescents with ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B(4):485-490.
34. Kraus M.S., Keefe R.S. Cognition as an outcome measure in schizophrenia. Br. J. Psychiatry 2007, 50:46-51.
35. Laurel A.T., Ross M.G.N., Ashok K.M., Anita D.R., Rashid R.A. Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders. Psychiatry Res. 2002, 113:69-81.
36. Laurent H., Leonie C., Laure J., Bernard P., Caroline S., Olivier H., Christopher R. Detection of cognitive impairment with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in adolescents with psychotic symptomatology. Schizophr. Res. 2007, 95:48-56.
37. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50(11):884-897.
38. Montague P.R., Hyman S.E., Cohen J.D. Computational roles for dopamine in behavioural control. Nature 2004, 431:760-767.
39. Nicoletta M.J., Matthijs V., Nick F.R., Rene S.K. Left dorsolateral prefrontal cortex dysfounciton in medication-naive schizophrenia. Schizophr. Res. 2010, 123(1):22-29.
40. Palmer A.M. Neurochemical studies of Alzheimer's disease. Neurodegeneration 1996, 5:381-391.
41. Parasuraman R., Greenwood P.M., Kumar R., Fossella J. Beyond heritability-neurotransmitter genes differentially modulate visuospatial attention and working memory. Psychol. Sci. 2005, 16:200-207.
42. Park J.K., Kim J.W., Lee H.J., Chung J.H., Ha E.Y., Oh D.J., Song J.Y. Dopamine beta-hydroxylase gene polymorphisms and psychotic symptoms in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B(7):944-945.
43. Rajji T.K., Mulsant B.H. Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr. Res. 2008, 102:122-140.
44. Rajji T.K., Ismail Z., Mulsant B.H. Age at onset and cognition in schizophrenia: meta-analysis. Br. J. Psychiatry 2009, 195:286-293.
45. Randolph C., Tierney M.C., Mohr E., Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 1998, 20:310-319.
46. Riley E.M., McGovern D., Mockler D., Duku V.C., Oceallaigh S., Fannon D.G., Tennakoon L., Santamaria M., Soni W., Morris R.G., Sharma T. Neuropsychological functioning in first-episode psychosis: evidence of specific deficits. Schizophr. Res. 2000, 43:47-55.
47. Rund B.R. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr. Bull. 1998, 24(3):425-435.
48. Ruth C., Jeffrey K.Y. Cognition, dopamine and bioactive lipids in schizophrenia. Front. Biosci. 2011, 3:298-330.
49. Sandra P.Z., Viladimir M.p., Yu T., Sun H.K., Peter Y., Evaristus N., Akira S., Mikhail V.P., Atsushi K. Working memory deficits in neuronal nitric oxide synthase knockout mice: Potential impairments in prefrontal cortex mediated cognitive function. Biochem. Biophys. Res. Commun. 2011, 408(4):707-712.
50. Stip E. Cognition, schizophrenia and the effect of antipsychotics. Encéphale 2006, 32:341-350.
51. Tan H.Y., Callicott J.H., Weinberger D.R. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn. Neuropsychiatry 2009, 14:277-298.
52. Tang Y.L., Epstein M.P., Anderson G.M., Zabetian C.P., Cubells J.F. Genotypic and haplotypic associations of the DBH gene with plasma dopamine betahydroxylase activity in African Americans. Eur. J. Hum. Genet. 2007, 15(8):878-883.
53. Terry A.V., Mahadik S.P. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J. Pharmacol. Exp. Ther. 2007, 320:961-968.
54. Togsverd M., Werge T.M., Tanko L.B., Bagger Y.Z., Qin G.G., Hansen T., Christiansen C., Rasmussen H.B. Cognitive performance in elderly women: significance of the 19bp insertion/deletion polymorphism in the 50 flank of the dopamine beta-hydroxylase gene, educational level, body fat measures, serum triglyceride, alcohol consumption and age. Int. J. Geriatr. Psychiatry 2007, 22:883-889.
55. White T., Ho B.C., Ward J., O'Leary D., Andreasen N.C. Neuropsychological performance in first-episode adolescents with schizophrenia: a comparison with first-episode adults and adolescent control subjects. Biol. Psychiatry 2006, 60:463-471.
56. Zabetian C.P., Anderson G.M., Buxbaum S.G., Elston R.C., Ichinose H., Nagatsu T., Kim K.S., Kim C.H., Malison R.T., Gelernter J., Cubells J.F. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am. J. Hum. Genet. 2001, 68:515-522.
57. Zhang B.H., Tan Y.L., Zhang W.F., Wang Z.R., Yang G.G., Shi C., Zhang X.Y., Zhou D.F. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a screening test in Chinese: reliability and validity. Chin. Ment. Health J. 2009, 28:865-869.
58. Zhang X.Y., Chen D.C., Xiu M.H., Haile C.N., Luo X., Xu K., Zhang H.P., Zuo L., Zhang Z., Zhang X., Kosten T.A., Kosten T.R. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum. Genet. 2012, 131(7):1187-1195.